Legend Biotech Corporation (LEGN)
NASDAQ: LEGN · Real-Time Price · USD
17.75
-0.10 (-0.56%)
At close: Mar 5, 2026, 4:00 PM EST
17.90
+0.15 (0.85%)
Pre-market: Mar 6, 2026, 4:09 AM EST
Legend Biotech Stock Forecast
Stock Price Forecast
The 13 analysts with 12-month price forecasts for Legend Biotech stock have an average target of 63.46, with a low estimate of 21 and a high estimate of 84. The average target predicts an increase of 257.52% from the current stock price of 17.75.
Analyst Consensus: Buy
* Price targets were last updated on Feb 4, 2026.
Analyst Ratings
The average analyst rating for Legend Biotech stock from 14 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 7 | 7 | 8 | 8 | 8 | 8 |
| Hold | 1 | 1 | 1 | 1 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 13 | 13 | 14 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Maintains $90 → $80 | Buy | Maintains | $90 → $80 | +350.70% | Feb 4, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $60 → $50 | Strong Buy | Maintains | $60 → $50 | +181.69% | Jan 22, 2026 |
| TD Cowen | TD Cowen | Strong Buy → Hold Downgrades $62 → $21 | Strong Buy → Hold | Downgrades | $62 → $21 | +18.31% | Jan 22, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $66 | Buy | Maintains | $66 | +271.83% | Jan 20, 2026 |
| Oppenheimer | Oppenheimer | Buy Initiates $75 | Buy | Initiates | $75 | +322.54% | Jan 7, 2026 |
Financial Forecast
Revenue This Year
1.05B
from 627.24M
Increased by 67.56%
Revenue Next Year
1.51B
from 1.05B
Increased by 43.20%
EPS This Year
-1.01
from -0.97
EPS Next Year
0.34
from -1.01
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 1.1B | 1.8B | ||||
| Avg | 1.1B | 1.5B | ||||
| Low | 976.1M | 1.3B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 81.6% | 68.1% | ||||
| Avg | 67.6% | 43.2% | ||||
| Low | 55.6% | 22.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | -0.66 | 0.71 | ||
| Avg | -1.01 | 0.34 | ||
| Low | -1.61 | -0.20 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | - | - | ||
| Avg | - | - | ||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.